I worked on this for multiple myeloma. DCA is nice but the concentrations you need for treating people gives them peripheral neuropathy, which isn’t trivial. But fwiw combining DCA with other drugs looks promising.
The issue is that cancer is polyclonal so there is a sub-population that predominantly relies of aerobic glycolysis, but the sub-populations that mostly metabolise glutamine or fatty acids will escape treatment... so you need a bit of a shotgun approach, in combination with traditional anti-cancer agents.
The issue is that cancer is polyclonal so there is a sub-population that predominantly relies of aerobic glycolysis, but the sub-populations that mostly metabolise glutamine or fatty acids will escape treatment... so you need a bit of a shotgun approach, in combination with traditional anti-cancer agents.